These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
527 related items for PubMed ID: 21481127
21. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ. Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170 [Abstract] [Full Text] [Related]
23. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial. Wang W, Nevárez L, Filippova E, Song KH, Tao B, Gu L, Wang F, Li P, Yang J. Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089 [Abstract] [Full Text] [Related]
24. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Blicklé JF, Hancu N, Piletic M, Profozic V, Shestakova M, Dain MP, Jacqueminet S, Grimaldi A. Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105 [Abstract] [Full Text] [Related]
25. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Lukashevich V, Del Prato S, Araga M, Kothny W. Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686 [Abstract] [Full Text] [Related]
30. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S. Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668 [Abstract] [Full Text] [Related]
31. Indirect comparison of lixisenatide versus neutral protamine Hagedorn insulin as add-on to metformin and sulphonylurea in patients with type 2 diabetes mellitus. Fournier M, Germe M, Theobald K, Scholz GH, Lehmacher W. Ger Med Sci; 2014 Jul; 12():Doc14. PubMed ID: 25332702 [Abstract] [Full Text] [Related]
33. Efficacy and Safety of Basal Insulin-Based Treatment Versus Twice-Daily Premixed Insulin After Short-Term Intensive Insulin Therapy in Patients with Type 2 Diabetes Mellitus in China: Study Protocol for a Randomized Controlled Trial (BEYOND V). Liu J, Jiang X, Xu B, Wang G, Cui N, Zhang X, Liu J, Mu Y, Guo L. Adv Ther; 2020 Apr; 37(4):1675-1687. PubMed ID: 32130661 [Abstract] [Full Text] [Related]
34. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy. Hollander P, Sugimoto D, Vlajnic A, Kilo C. J Diabetes Complications; 2015 Apr; 29(8):1266-71. PubMed ID: 26281972 [Abstract] [Full Text] [Related]
36. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, Montanaro M, Fisher SA. Diabetes Obes Metab; 2014 May; 16(5):443-50. PubMed ID: 24205943 [Abstract] [Full Text] [Related]
37. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study. Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P. Endocr Pract; 2011 May; 17(1):41-50. PubMed ID: 20713345 [Abstract] [Full Text] [Related]
38. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. Lingvay I, Pérez Manghi F, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB, DUAL V Investigators. JAMA; 2016 Mar 01; 315(9):898-907. PubMed ID: 26934259 [Abstract] [Full Text] [Related]